Brain metastasis

So with ROS1 in someone that's newly diagnosed, the likelihood is about one out of four, so 25%.

But lifetime on any therapy, it, it can go up to half of patients that present with brain metastases.

Crizotinib is decent at inhibiting ROS1 cancer that's gone to the brain.

The response rate is 72%.

Um, so that'll be kind of an exciting, um, way to go moving forward, I think, 'cause the, the responses now we're seeing in that other population are so robust that- We really don't know now what's the optimal timing of local therapy? Is it needed at all? Um, and then what should surveillance look like moving forward, too? So lots of questions, which is exciting in this space, where we really hadn't had much movement for a very, very long time.

Let's jump then to some brain metastases abstracts.

We'll touch on first ALLIANCE A071801, single fraction versus fractionated SRS.

This is a question that radiosurgery has really circled around for decades without a randomized answer.

On to NRG CC009.

Could you go into what the significance of this study is?

So for small cell lung cancer brain metastases, it, small cell lung cancer had remained the one solid tumor type where whole-brain radiotherapy had really been a preferred treatment strategy.

And that was born out of the idea of PCI.